@prefix dcterms: .
@prefix ns1: .
@prefix this: .
@prefix sub: .
@prefix schema: .
@prefix np: .
@prefix rdf: .
@prefix nt: .
@prefix xsd: .
@prefix rdfs: .
@prefix orcid: .
@prefix bl: .
@prefix npx: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo;
a np:Nanopublication .
}
sub:assertion {
bl:category bl:Disease .
sub:association rdf:object ;
rdf:predicate bl:treats;
rdf:subject ;
a rdf:Statement;
rdfs:label "paclitaxel injection usp is indicated as first line and subsequent therapy for the treatment of advanced carcinoma of the ovary as first line therapy paclitaxel injection usp is indicated in combination with cisplatin paclitaxel injection usp is indicated for the adjuvant treatment of node positive breast cancer administered sequentially to standard doxorubicin containing combination chemotherapy in the clinical trial there was an overall favorable effect on disease free and overall survival in the total population of patients with receptor positive and receptor negative tumors but the benefit has been specifically demonstrated by available data median follow up 3 months only in the patients with estrogen and progesterone receptor negative tumors see clinical studies breast carcinoma paclitaxel injection usp is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy prior therapy should have included an anthracycline unless clinically contraindicated paclitaxel injection usp in combination with cisplatin is indicated for the first line treatment of non small cell lung cancer in patients who are not candidates for potentially curative surgery and or radiation therapy paclitaxel injection usp is indicated for the second line treatment of aids related kaposi s sarcoma";
bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
bl:provided_by ;
bl:relation schema:TreatmentIndication .
bl:category bl:Drug .
}
sub:provenance {
sub:assertion ns1:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
npx:hasSignature "Pn2mLQBX5CCYVJBGpGNz8PGEnZjVVG7IoEZp4GWlrlFqkcB6+toC9oQmL4jOT4Xyn4TvzRg8wi+zVsoUuf32qdRv9EsieP8ml+IsOklcV5auol+W76paEAQz427cuTCaNHbruiaquQ8cZX7ohNOqLzILPJsijr7tunvN0/dGqEE=";
npx:hasSignatureTarget this: .
this: dcterms:created "2021-06-27T20:16:36.924+02:00"^^xsd:dateTime;
dcterms:creator orcid:0000-0002-1468-3557;
nt:wasCreatedFromProvenanceTemplate ;
nt:wasCreatedFromPubinfoTemplate ;
nt:wasCreatedFromTemplate .
}